Galectin Therapeutics (GALT) Common Equity (2010 - 2026)

Galectin Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at -$132.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 15.77% year-over-year to -$132.0 million; the TTM figure through Mar 2026 stood at -$132.0 million (down 15.77% YoY), while the FY2025 annual figure was -$127.9 million, down 22.07% from the prior year.
• Common Equity for Q1 2026 stood at -$132.0 million, down from -$127.9 million in the prior quarter.
• The five-year high for Common Equity was -$7.9 million in Q1 2022, with the low at -$132.0 million in Q1 2026.
• The 5-year median for Common Equity is -$62.0 million (2023), against an average of -$72.9 million.
• The sharpest annual moves came in 2022 and 2024: Common Equity slumped 3898.1% in 2022, then changed 0.0% in 2024.
• Galectin Therapeutics' Common Equity stood at -$33.9 million in 2022, then slumped by 82.69% to -$62.0 million in 2023, then sank by 69.12% to -$104.8 million in 2024, then decreased by 22.07% to -$127.9 million in 2025, then slipped by 3.16% to -$132.0 million in 2026.
• Business Quant data shows GALT's Common Equity at -$132.0 million in Q1 2026, -$127.9 million in Q4 2025, and -$125.3 million in Q3 2025.